Constitutive β-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development

Human Molecular Genetics

Volumn 19, Issue 8, 2010, Pages 1561-1576

  Berthon, Annabel ^a,b   Sahut Barnola, Isabelle ^a,b   Lambert Langlais, Sarah ^a,b   de Joussineau, Cyrille ^a,b   Damon Soubeyrand, Christelle ^a,b   Louiset, Estelle ^c   Taketo, Mark M ^d   Tissier, Frédérique ^e,f,g   Bertherat, Jérôme ^e,f,g   Lefrançois Martinez, Anne Marie ^a,b   Martinez, Antoine ^a,b   Val, Pierre ^a,b  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b CNRS   (France)

^c UNIVERSITÉ DE ROUEN   (France)

^d KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e INSTITUT COCHIN   (France)

^f INSERM   (France)

^g université Paris Cité   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AXIN; BETA CATENIN; CRE RECOMBINASE; CYCLIN D1; GLYCOGEN SYNTHASE KINASE 3BETA; THROMBOSPONDIN 1; VASCULOTROPIN A; WNT PROTEIN;

ADRENAL CANCER; ADRENAL HYPERPLASIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; EXON; HYPERALDOSTERONISM; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPINDLE CELL; UPREGULATION; WESTERN BLOTTING;

ADRENAL CORTEX; ADRENAL GLAND NEOPLASMS; ALDOSTERONE; ANIMALS; BETA CATENIN; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HUMANS; HYPERPLASIA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM METASTASIS;

MUS MUSCULUS;

EID: 77952300541     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddq029     Document Type: Article

References (65)

1. Wajchenberg, B.L., Albergaria Pereira, M.A., Medonca, B.B., Latronico, A.C., Campos Carneiro, P., Alves, V.A., Zerbini, M.C., Liberman, B., Carlos Gomes, G. and Kirschner, M.A. (2000) Adrenocortical carcinoma: clinical and laboratory observations. Cancer, 88, 711-736.
2. Allolio, B. and Fassnacht, M. (2006) Clinical review: Adrenocortical carcinoma: clinical update. J. Clin. Endocrinol. Metab., 91, 2027-2037.
3. Icard, P., Goudet, P., Charpenay, C., Andreassian, B., Carnaille, B., Chapuis, Y., Cougard, P., Henry, J.F. and Proye, C. (2001) Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J. Surg., 25, 891-897.
4. Bernard, M.H., Sidhu, S., Berger, N., Peix, J.L., Marsh, D.J., Robinson, B.G., Gaston, V., Le Bouc, Y. and Gicquel, C. (2003) A case report in favor of a multistep adrenocortical tumorigenesis. J. Clin. Endocrinol. Metab., 88, 998-1001.
5. Gicquel, C., Leblond-Francillard, M., Bertagna, X., Louvel, A., Chapuls, Y., Luton, J.P., Girard, F. and Le Bouc, Y. (1994) Clonal analysis of human adrenocortical carcinomas and secreting adenomas. Clin. Endocrinol. (Oxf), 40, 465-477.
6. Gicquel, C., Baudin, E., Le Bouc, Y. and Schlumberger, M. (1997) Adrenal carcinoma. Ann. Oncol., 8,1-5.
7. de Fraipont, F., El Atifi, M., Cherradi, N., Le Moigne, G., Defaye, G., Houlgatte, R., Bertherat, J., Bertagna, X., Plouin, P.F., Baudin, E. et al. (2005) Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. J. Clin. Endocrinol. Metab., 90, 1819-1829.
8. Giordano, T.J., Thomas, D.G., Kuick, R., Lizyness, M., Misek, D.E., Smith, A.L., Sanders, D., Aljundi, R.T., Gauger, P.G., Thompson, N.W. et al. (2003) Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am. J. Pathol., 162, 521-531.
9. West, A.N., Neale, G.A., Pounds, S., Figueredo, B.C., Rodriguez Galindo, C., Pianovski, M.A., Oliveira Filho, A.G., Malkin, D., Lalli, E., Ribeiro, R. et al. (2007) Gene expression profiling of childhood adrenocortical tumors. Cancer Res., 67, 600-608.
10. Barlaskar, F.M., Spalding, A.C., Heaton, J.H., Kuick, R., Kim, A.C., Thomas, D.G., Giordano, T.J., Ben-Josef, E. and Hammer, G.D. (2009) Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J. Clin. Endocrinol. Metab., 94, 204-212.
11. Caspary, T., Cleary, M.A., Perlman, E.J., Zhang, P., Elledge, S.J. and Tilghman, S.M. (1999) Oppositely imprinted genes p57(Kip2) and igf2 interact in a mouse model for Beckwith-Wiedemann syndrome. Genes Dev., 13, 3115-3124.
12. Ribeiro, R.C., Sandrini, F., Figueiredo, B., Zambetti, G., Michalkiewicz, E., Lafferty, A., Delacerda, L., Rabin, M., Cadwell, C., Sampaio, G. et al. (2001) An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc. Natl Acad. Sci. USA., 98, 9330-9335.
13. Libe, R., Groussin, L., Tissier, F., Elie, C., Rene-Corail, F., Fratticci, A., Jullian, E., Beck-Peccoz, P., Bertagna, X., Gicquel, C. et al. (2007) Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin. Cancer Res., 13, 844-850.
14. Harvey, M., McArthur, M.J., Montgomery, C.A. Jr, Butel, J.S., Bradley, A. and Donehower, L.A. (1993) Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat. Genet., 5, 225-229.
15. Smith, T.G., Clark, S.K., Katz, D.E., Reznek, R.H. and Phillips, R.K. (2000) Adrenal masses are associated with familial adenomatous polyposis. Dis. Colon. Rectum., 43, 1739-1742.
16. Fuerer, C., Nusse, R. and Ten Berge, D. (2008) Wnt signalling in development and disease. Max Delbruck Center for Molecular Medicine meeting on Wnt signaling in Development and Disease. EMBO Rep., 9, 134-138.
17. Cadigan, K.M. and Nusse, R. (1997) Wnt signaling: a common theme in animal development. Genes Dev., 11, 3286-3305.
18. Gregorieff, A. and Clevers, H. (2005) Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev., 19, 877-890.
19. Polakis, P. (2000) Wnt signaling and cancer. Genes Dev., 14, 1837-1851.
20. Galiatsatos, P. and Foulkes, W.D. (2006) Familial adenomatous polyposis. Am. J. Gastroenterol., 101, 385-398.
21. Kim, A.C., Reuter, A.L., Zubair, M., Else, T., Serecky, K., Bingham, N.C., Lavery, G.G., Parker, K.L. and Hammer, G.D. (2008) Targeted disruption of beta-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex. Development, 135, 2593-2602.
22. Tissier, F., Cavard, C., Groussin, L., Perlemoine, K., Fumey, G., Hagnere, A.M., Rene-Corail, F., Jullian, E., Gicquel, C., Bertagna, X. et al. (2005) Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res., 65, 7622-7627.
23. Gaujoux, S., Tissier, F., Groussin, L., Libe, R., Ragazzon, B., Launay, P., Audebourg, A., Dousset, B., Bertagna, X. and Bertherat, J. (2008) Wnt/beta-catenin and 3′ ,5′-cyclic adenosine 5′-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors. J. Clin. Endocrinol. Metab., 93, 4135-4140.
24. Tadjine, M., Lampron, A., Ouadi, L., Horvath, A., Stratakis, C.A. and Bourdeau, I. (2008) Detection of somatic beta-catenin mutations in primary pigmented nodular adrenocortical disease. Clin. Endocrinol. (Oxf), 69, 367-373.
25. Tadjine, M., Lampron, A., Ouadi, L. and Bourdeau, I. (2008) Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas. Clin. Endocrinol. (Oxf), 68, 264-270.
26. Doghman, M., Cazareth, J. and Lalli, E. (2008) The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. J. Clin. Endocrinol. Metab., 93, 3222-3225.
27. Harada, N., Tamai, Y., Ishikawa, T., Sauer, B., Takaku, K., Oshima, M. and Taketo, M.M. (1999) Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J., 18, 5931-5942.
28. Lambert-Langlais, S., Val, P., Guyot, S., Ragazzon, B., Sahut-Barnola, I., De Haze, A., Lefrancois-Martinez, A.M. and Martinez, A. (2009) A transgenic mouse line with specific Cre recombinase expression in the adrenal cortex. Mol. Cell. Endocrinol., 300, 197-204.
29. Lustig, B., Jerchow, B., Sachs, M., Weiler, S., Pietsch, T., Karsten, U., van de Wetering, M., Clevers, H., Schlag, P.M., Birchmeier, W. et al. (2002) Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol. Cell. Biol., 22, 1184-1193.
30. Val, P., Lefrancois Martinez, A.M., Veyssiere, G. and Martinez, A. (2003) SF-1 a key player in the development and differentiation of steroidogenic tissues. Nucl. Recept., 1.
31. Bielinska, M., Kiiveri, S., Parviainen, H., Mannisto, S., Heikinheimo, M. and Wilson, D.B. (2006) Gonadectomy-induced adrenocortical neoplasia in the domestic ferret (mustela putorius furo) and laboratory mouse. Vet. Pathol., 43, 97-117.
32. Kiiveri, S., Liu, J., Heikkila, P., Arola, J., Lehtonen, E., Voutilainen, R. and Heikinheimo, M. (2004) Transcription factors GATA-4 and GATA-6 in human adrenocortical tumors. Endocr. Res., 30, 919-923.
33. Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., D'Amico, M., Pestell, R. and Ben-Ze'ev, A. (1999) The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc. Natl Acad. Sci. USA., 96, 5522-5527.
34. Heikkila, M., Peltoketo, H., Leppaluoto, J., Ilves, M., Vuolteenaho, O. and Vainio, S. (2002) Wnt-4 deficiency alters mouse adrenal cortex function, reducing aldosterone production. Endocrinology, 143, 4358-4365.
35. Hanahan, D. and Weinberg, R.A. (2000) The hallmarks of cancer. Cell, 100, 57-70.
36. Magennis, D.P. and McNicol, A.M. (1998) Vascular patterns in the normal and pathological human adrenal cortex. Virchows Arch. A. Pathol. Anat. Histopathol., 433, 69-73.
37. de Fraipont, F., El Atifi, M., Gicquel, C., Bertagna, X., Chambaz, E.M. and Feige, J.J. (2000) Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations. J. Clin. Endocrinol. Metab., 85, 4734-4741.
38. Clifford, R.L., Deacon, K. and Knox, A.J. (2008) Novel regulation of vascular endothelial growth factor-A (VEGF-A) by transforming growth factor (beta)1: requirement for Smads, (beta)-CATENIN, AND GSK3(beta). J. Biol. Chem., 283, 35337-35353.
39. Grigoryan, T., Wend, P., Klaus, A. and Birchmeier, W. (2008) Deciphering the function of canonical Wnt signals in development and disease: conditional lossand gain-of-function mutations of beta-catenin in mice. Genes Dev., 22, 2308-2341.
40. Phelps, R.A., Chidester, S., Dehghanizadeh, S., Phelps, J., Sandoval, I.T., Rai, K., Broadbent, T., Sarkar, S., Burt, R.W. and Jones, D.A. (2009) A two-step model for colon adenoma initiation and progression caused by APC loss. Cell., 137, 623-634.
41. Verras, M. and Sun, Z. (2005) Beta-catenin is involved in insulin-like growth factor 1-mediated transactivation of the androgen receptor. Mol. Endocrinol., 19, 391-398.
42. Sawyer, E.J., Hanby, A.M., Poulsom, R., Jeffery, R., Gillett, C.E., Ellis, I.O., Ellis, P. and Tomlinson, I.P. (2003) Beta-catenin abnormalities and associated insulin-like growth factor overexpression are important in phyllodes tumours and fibroadenomas of the breast. J. Pathol., 200, 627-632.
43. Ding, Q., Xia, W., Liu, J.C., Yang, J.Y., Lee, D.F., Xia, J., Bartholomeusz, G., Li, Y., Pan, Y., Li, Z. et al. (2005) Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol. Cell., 19, 159-170.
44. Cross, D.A., Alessi, D.R., Cohen, P., Andjelkovich, M. and Hemmings, B.A. (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature, 378, 785-789.
45. Doghman, M., Arhatte, M., Thibout, H., Rodrigues, G., De Moura, J., Grosso, S., West, A.N., Laurent, M., Mas, J.C., Bongain, A. et al. (2007) Nephroblastoma overexpressed/cysteine-rich protein 61/connective tissue growth factor/nephroblastoma overexpressed gene-3 (NOV/CCN3), a selective adrenocortical cell proapoptotic factor, is down-regulated in childhood adrenocortical tumors. J. Clin. Endocrinol. Metab., 92, 3253-3260.
46. Martinerie, C., Gicquel, C., Louvel, A., Laurent, M., Schofield, P.N. and Le Bouc, Y. (2001) Altered expression of novH is associated with human adrenocortical tumorigenesis. J. Clin. Endocrinol. Metab., 86, 3929-3940.
47. Murray, S.A., Davis, K., Fishman, L.M. and Bornstein, S.R. (2000) Alpha1 connexin 43 gap junctions are decreased in human adrenocortical tumors. J. Clin. Endocrinol. Metab., 85, 890-895.
48. Bernichtein, S., Petretto, E., Jamieson, S., Goel, A., Aitman, T.J., Mangion, J.M. and Huhtaniemi, I.T. (2008) Adrenal gland tumorigenesis after gonadectomy in mice is a complex genetic trait driven by epistatic loci. Endocrinology, 149, 651-661.
49. Kananen, K., Markkula, M., Mikola, M., Rainio, E.M., McNeilly, A.S. and Huhtaniemi, I. (1996) Gonadectomy permits adrenocortical tumorigenesis in mice transgenic for the mouse inhibin α-subunit promoter/simian virus 40 T-antigen fusion gene: evidence for negative autoregulation of the inhibin α-subunit gene. Mol. Endocrinol., 10, 1667-1677.
50. Matzuk, M.M., Finegold, M.J., Mather, J.P., Krummen, L., Lu, H. and Bradley, A. (1994) Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc. Natl Acad. Sci. USA., 91, 8817-8821.
51. Looyenga, B.D. and Hammer, G.D. (2006) Origin and identity of adrenocortical tumors in inhibin knockout mice: implications for cellular plasticity in the adrenal cortex. Mol. Endocrinol., 20, 2848-2863.
52. Doghman, M., Karpova, T., Rodrigues, G.A., Arhatte, M., De Moura, J., Cavalli, L.R., Virolle, V., Barbry, P., Zambetti, G.P., Figueiredo, B.C. et al. (2007) Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer. Mol. Endocrinol., 21, 2968-2987.
53. Bhandaru, M., Kempe, D.S., Rotte, A., Rexhepaj, R., Kuhl, D. and Lang, F. (2009) Hyperaldosteronism, hypervolemia, and increased blood pressure in mice expressing defective APC. Am. J. Physiol. Regul. Integr. Comp. Physiol., 297, R571-R575.
54. Schirpenbach, C., Segmiller, F., Diederich, S., Hahner, S., Lorenz, R., Rump, L.C., Seufert, J., Quinkler, M., Bidlingmaier, M., Beuschlein, F. et al. (2009) The diagnosis and treatment of primary hyperaldosteronism in Germany: results on 555 patients from the German Conn Registry. Dtsch. Arztebl. Int., 106, 305-311.
55. Abma, E.M., Kluin, P.M. and Dullaart, R.P. (2008) Malignant aldosterone-producing adrenal tumour: reoccurrence with glucocorticoid excess without hyperaldosteronism. Neth. J. Med., 66, 252-255.
56. Barzon, L., Masi, G., Fincati, K., Pacenti, M., Pezzi, V., Altavilla, G., Fallo, F. and Palu, G. (2005) Shift from Conn's syndrome to Cushing's syndrome in a recurrent adrenocortical carcinoma. Eur. J. Endocrinol., 153, 629-636.
57. Sweeney, A.T., Blake, M.A., Aish, L.S., Pais, V.M., Dowling, J.J., Melby, J.C. and Tully, G.L. III. (2002) A malignant aldosteronoma. Endocr. Pract., 8, 373-377.
58. Seccia, T.M., Fassina, A., Nussdorfer, G.G., Pessina, A.C. and Rossi, G.P. (2005) Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocr. Relat. Cancer, 12, 149-159.
59. Keegan, C.E. and Hammer, G.D. (2002) Recent insights into organogenesis of the adrenal cortex. Trends Endocrinol. Metab., 13, 200-208.
60. Benhamouche, S., Decaens, T., Godard, C., Chambrey, R., Rickman, D.S., Moinard, C., Vasseur-Cognet, M., Kuo, C.J., Kahn, A., Perret, C. et al. (2006) Apc tumor suppressor gene is the 'zonation-keeper' of mouse liver. Dev. Cell., 10, 759-770.
61. Heitzmann, D., Derand, R., Jungbauer, S., Bandulik, S., Sterner, C., Schweda, F., El Wakil, A., Lalli, E., Guy, N., Mengual, R. et al. (2008) Invalidation of TASK1 potassium channels disrupts adrenal gland zonation and mineralocorticoid homeostasis. EMBO J., 27, 179-187.
62. Kim, A.C., Barlaskar, F.M., Heaton, J.H., Else, T., Kelly, V.R., Krill, K.T., Scheys, J.O., Simon, D.P., Trovato, A., Yang, W.H. et al. (2009) In search of adrenocortical stem and progenitor cells. Endocr. Rev., 30, 241-263.
63. King, P., Paul, A. and Laufer, E. (2009) Shh signaling regulates adrenocortical development and identifies progenitors of steroidogenic lineages. Proc. Natl Acad. Sci. USA., 106, 21185-21190.
64. Jiang, J. and Hui, C.C. (2008) Hedgehog signaling in development and cancer. Dev. Cell., 15, 801-812.
65. Lefrancois-Martinez, A.M., Bertherat, J., Val, P., Tournaire, C., Veyssiere, G., Jean, C. and Martinez, A. (2004) Decreased expression of cyclic adenosine monophosphate-regulated aldose reductase (AKR1B1) is associated with malignancy in human sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab., 89, 3010-3019.